118 related articles for article (PubMed ID: 31902291)
1. Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans.
Rioux N; Smith S; Colombo F; Kim A; Lai WG; Nix D; Siu YA; Schindler J; Smith PG
Xenobiotica; 2020 Sep; 50(9):1101-1114. PubMed ID: 31902291
[TBL] [Abstract][Full Text] [Related]
2. Correlation of the
Colombo F; Smith S; Lai GW; Nix D; Smith PG; Schindler J; Rioux N
Xenobiotica; 2020 Apr; 50(4):458-467. PubMed ID: 31305210
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
Spinello A; Borišek J; Malcovati L; Magistrato A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.
Banijamali AR; Carvalho AE; Wakefield JD; Germano P; Barden TC; Tobin JV; Zimmer DP; Masferrer JL; Profy AT; Currie MG; Todd Milne G
Pharmacol Res Perspect; 2020 Apr; 8(2):e00579. PubMed ID: 32314550
[TBL] [Abstract][Full Text] [Related]
6. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
8. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
[TBL] [Abstract][Full Text] [Related]
9. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
Emary WB; Toren PC; Mathews B; Huh K
Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys.
Tachibana M; Tanaka M; Mitsugi K; Jin Y; Takaichi M; Okazaki O
Arzneimittelforschung; 2004; 54(12):898-905. PubMed ID: 15646375
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
15. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
16. Disposition of SK&F L-190144 in rats and monkeys after oral, intravenous or ocular administration.
Tang-Liu DD; Richman JB; Lin P; Selim S
Biopharm Drug Dispos; 1993 May; 14(4):313-24. PubMed ID: 8499582
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
Yue Q; Mulder T; Rudewicz PJ; Solon E; Budha N; Ware JA; Lyssikatos J; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2013 Feb; 41(2):508-17. PubMed ID: 23223496
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey.
Salmon J; Coussediere D; Cousty C; Raynaud JP
J Steroid Biochem; 1983 Aug; 19(2):1223-34. PubMed ID: 6887930
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
Stüben J; Port R; Bertram B; Bollow U; Hull WE; Schaper M; Pohl J; Wiessler M
Cancer Chemother Pharmacol; 1996; 38(4):355-65. PubMed ID: 8674159
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, distribution, metabolism and excretion of.
Yasoshima K; Kuwabara T; Fuse E; Kuramitu T; Kurata N; Nishiie H; Oishi T; Kobayashi H; Kobayashi S
Cancer Chemother Pharmacol; 2001; 47(2):106-12. PubMed ID: 11269735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
